Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...
Beta Bionics has announced the pricing of its upsized initial public offering of 12 million shares of common stock at a price to the public of $17 per share.